Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

BACKGROUND: Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti–CTLA-4 treatment prolongs overall survival in patients with melanom...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Main Authors: Snyder, Alexandra, Makarov, Vladimir, Merghoub, Taha, Yuan, Jianda, Zaretsky, Jesse M., Desrichard, Alexis, Walsh, Logan A., Postow, Michael A., Wong, Phillip, Ho, Teresa S., Hollmann, Travis J., Bruggeman, Cameron, Kannan, Kasthuri, Li, Yanyun, Elipenahli, Ceyhan, Liu, Cailian, Harbison, Christopher T., Wang, Lisu, Ribas, Antoni, Wolchok, Jedd D., Chan, Timothy A.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4315319/
https://ncbi.nlm.nih.gov/pubmed/25409260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1406498
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares